APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urea Cycle Disorder Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urea Cycle Disorder Agent Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchUrea Cycle Disorder Agent Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Urea Cycle Disorder Agent Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Urea Cycle Disorder Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urea Cycle Disorder Agent Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Urea Cycle Disorder Agent Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Urea Cycle Disorder Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urea Cycle Disorder Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urea Cycle Disorder Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urea Cycle Disorder Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urea Cycle Disorder Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urea Cycle Disorder Agent market include Amgen, Sigmapharm Laboratories, Medunik, Lee's Pharmaceutical, Immedica, Horizon Pharma and Acer Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Urea Cycle Disorder Agent market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urea Cycle Disorder Agent and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urea Cycle Disorder Agent revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Urea Cycle Disorder Agent market.

Urea Cycle Disorder Agent Segment by Company

Amgen

Sigmapharm Laboratories

Medunik

Lee's Pharmaceutical

Immedica

Horizon Pharma

Acer Therapeutics

Urea Cycle Disorder Agent Segment by Type

Glycerol Phenylbutyrate

Sodium Phenylbutyrate

Urea Cycle Disorder Agent Segment by Application

Hospital

Pharmacy

Urea Cycle Disorder Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Urea Cycle Disorder Agent status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Urea Cycle Disorder Agent key companies, revenue, market share, and recent developments.

3. To split the Urea Cycle Disorder Agent breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Urea Cycle Disorder Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urea Cycle Disorder Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Urea Cycle Disorder Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urea Cycle Disorder Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urea Cycle Disorder Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urea Cycle Disorder Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urea Cycle Disorder Agent industry.

Chapter 3: Detailed analysis of Urea Cycle Disorder Agent company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Urea Cycle Disorder Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Urea Cycle Disorder Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urea Cycle Disorder Agent Industry Trends Table 2. Urea Cycle Disorder Agent Industry Drivers Table 3. Urea Cycle Disorder Agent Industry Opportunities and Challenges Table 4. Urea Cycle Disorder Agent Industry Restraints Table 5. Global Urea Cycle Disorder Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urea Cycle Disorder Agent Revenue Share by Company (2021-2026) Table 7. Global Urea Cycle Disorder Agent Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Urea Cycle Disorder Agent Key Company Manufacturing Base & Headquarters Table 9. Global Urea Cycle Disorder Agent Company, Product Type & Application Table 10. Global Urea Cycle Disorder Agent Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Urea Cycle Disorder Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Glycerol Phenylbutyrate Table 15. Significant Companies of Sodium Phenylbutyrate Table 16. Global Urea Cycle Disorder Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Urea Cycle Disorder Agent Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Urea Cycle Disorder Agent Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Urea Cycle Disorder Agent Sales Value Share by Type (2021-2026) Table 20. Global Urea Cycle Disorder Agent Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Pharmacy Table 23. Global Urea Cycle Disorder Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Urea Cycle Disorder Agent Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Urea Cycle Disorder Agent Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Urea Cycle Disorder Agent Sales Value Share by Application (2021-2026) Table 27. Global Urea Cycle Disorder Agent Sales Value Share by Application (2027-2032) Table 28. Global Urea Cycle Disorder Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Urea Cycle Disorder Agent Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Urea Cycle Disorder Agent Sales Value Share by Region (2021-2026) Table 31. Global Urea Cycle Disorder Agent Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Urea Cycle Disorder Agent Sales Value Share by Region (2027-2032) Table 33. Global Urea Cycle Disorder Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Urea Cycle Disorder Agent Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Urea Cycle Disorder Agent Sales Value Market Share by Country (2021-2026) Table 36. Global Urea Cycle Disorder Agent Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Urea Cycle Disorder Agent Sales Value Market Share by Country (2027-2032) Table 38. Amgen Company Information Table 39. Amgen Business Overview Table 40. Amgen Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Amgen Urea Cycle Disorder Agent Product Portfolio Table 42. Amgen Recent Development Table 43. Sigmapharm Laboratories Company Information Table 44. Sigmapharm Laboratories Business Overview Table 45. Sigmapharm Laboratories Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sigmapharm Laboratories Urea Cycle Disorder Agent Product Portfolio Table 47. Sigmapharm Laboratories Recent Development Table 48. Medunik Company Information Table 49. Medunik Business Overview Table 50. Medunik Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Medunik Urea Cycle Disorder Agent Product Portfolio Table 52. Medunik Recent Development Table 53. Lee's Pharmaceutical Company Information Table 54. Lee's Pharmaceutical Business Overview Table 55. Lee's Pharmaceutical Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Lee's Pharmaceutical Urea Cycle Disorder Agent Product Portfolio Table 57. Lee's Pharmaceutical Recent Development Table 58. Immedica Company Information Table 59. Immedica Business Overview Table 60. Immedica Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Immedica Urea Cycle Disorder Agent Product Portfolio Table 62. Immedica Recent Development Table 63. Horizon Pharma Company Information Table 64. Horizon Pharma Business Overview Table 65. Horizon Pharma Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Horizon Pharma Urea Cycle Disorder Agent Product Portfolio Table 67. Horizon Pharma Recent Development Table 68. Acer Therapeutics Company Information Table 69. Acer Therapeutics Business Overview Table 70. Acer Therapeutics Urea Cycle Disorder Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Acer Therapeutics Urea Cycle Disorder Agent Product Portfolio Table 72. Acer Therapeutics Recent Development Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Urea Cycle Disorder Agent Product Image Figure 2. Global Urea Cycle Disorder Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urea Cycle Disorder Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Urea Cycle Disorder Agent Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Glycerol Phenylbutyrate Image Figure 8. Sodium Phenylbutyrate Image Figure 9. Global Urea Cycle Disorder Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Urea Cycle Disorder Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Urea Cycle Disorder Agent Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Pharmacy Image Figure 14. Global Urea Cycle Disorder Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Urea Cycle Disorder Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Urea Cycle Disorder Agent Sales Value Share by Application (2021-2032) Figure 17. Global Urea Cycle Disorder Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Urea Cycle Disorder Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Urea Cycle Disorder Agent Sales Value (2021-2032) & (US$ Million) Figure 20. North America Urea Cycle Disorder Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Urea Cycle Disorder Agent Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Urea Cycle Disorder Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Urea Cycle Disorder Agent Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Urea Cycle Disorder Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Urea Cycle Disorder Agent Sales Value (2021-2032) & (US$ Million) Figure 26. South America Urea Cycle Disorder Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Urea Cycle Disorder Agent Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Urea Cycle Disorder Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Glycerol Phenylbutyrate
  • Sodium Phenylbutyrate
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Amgen
  • Sigmapharm Laboratories
  • Medunik
  • Lee's Pharmaceutical
  • Immedica
  • Horizon Pharma
  • Acer Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urea Cycle Disorder Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urea Cycle Disorder Agent Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Urea Cycle Disorder Agent Market Dynamics
  1. 2.1 Urea Cycle Disorder Agent Industry Trends
  2. 2.2 Urea Cycle Disorder Agent Industry Drivers
  3. 2.3 Urea Cycle Disorder Agent Industry Opportunities and Challenges
  4. 2.4 Urea Cycle Disorder Agent Industry Restraints
3 Urea Cycle Disorder Agent Market by Company
  1. 3.1 Global Urea Cycle Disorder Agent Company Revenue Ranking in 2025
  2. 3.2 Global Urea Cycle Disorder Agent Revenue by Company (2021-2026)
  3. 3.3 Global Urea Cycle Disorder Agent Company Ranking (2024-2026)
  4. 3.4 Global Urea Cycle Disorder Agent Company Manufacturing Base and Headquarters
  5. 3.5 Global Urea Cycle Disorder Agent Company Product Type and Application
  6. 3.6 Global Urea Cycle Disorder Agent Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Urea Cycle Disorder Agent Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Urea Cycle Disorder Agent Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Urea Cycle Disorder Agent Market by Type
  1. 4.1 Urea Cycle Disorder Agent Type Introduction
  2. 4.1.1 Glycerol Phenylbutyrate
  3. 4.1.2 Sodium Phenylbutyrate
  4. 4.2 Global Urea Cycle Disorder Agent Sales Value by Type
  5. 4.2.1 Global Urea Cycle Disorder Agent Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urea Cycle Disorder Agent Sales Value by Type (2021-2032)
  7. 4.2.3 Global Urea Cycle Disorder Agent Sales Value Share by Type (2021-2032)
5 Urea Cycle Disorder Agent Market by Application
  1. 5.1 Urea Cycle Disorder Agent Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Urea Cycle Disorder Agent Sales Value by Application
  5. 5.2.1 Global Urea Cycle Disorder Agent Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Urea Cycle Disorder Agent Sales Value by Application (2021-2032)
  7. 5.2.3 Global Urea Cycle Disorder Agent Sales Value Share by Application (2021-2032)
6 Urea Cycle Disorder Agent Regional Value Analysis
  1. 6.1 Global Urea Cycle Disorder Agent Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urea Cycle Disorder Agent Sales Value by Region (2021-2032)
  3. 6.2.1 Global Urea Cycle Disorder Agent Sales Value by Region: 2021-2026
  4. 6.2.2 Global Urea Cycle Disorder Agent Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urea Cycle Disorder Agent Sales Value (2021-2032)
  7. 6.3.2 North America Urea Cycle Disorder Agent Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Urea Cycle Disorder Agent Sales Value (2021-2032)
  10. 6.4.2 Europe Urea Cycle Disorder Agent Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Urea Cycle Disorder Agent Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Urea Cycle Disorder Agent Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Urea Cycle Disorder Agent Sales Value (2021-2032)
  16. 6.6.2 South America Urea Cycle Disorder Agent Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Urea Cycle Disorder Agent Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Urea Cycle Disorder Agent Sales Value Share by Country, 2025 VS 2032
7 Urea Cycle Disorder Agent Country-level Value Analysis
  1. 7.1 Global Urea Cycle Disorder Agent Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urea Cycle Disorder Agent Sales Value by Country (2021-2032)
  3. 7.2.1 Global Urea Cycle Disorder Agent Sales Value by Country (2021-2026)
  4. 7.2.2 Global Urea Cycle Disorder Agent Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Urea Cycle Disorder Agent Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Urea Cycle Disorder Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Urea Cycle Disorder Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Urea Cycle Disorder Agent Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Sigmapharm Laboratories
  8. 8.2.1 Sigmapharm Laboratories Company Information
  9. 8.2.2 Sigmapharm Laboratories Business Overview
  10. 8.2.3 Sigmapharm Laboratories Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sigmapharm Laboratories Urea Cycle Disorder Agent Product Portfolio
  12. 8.2.5 Sigmapharm Laboratories Recent Developments
  13. 8.3 Medunik
  14. 8.3.1 Medunik Company Information
  15. 8.3.2 Medunik Business Overview
  16. 8.3.3 Medunik Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Medunik Urea Cycle Disorder Agent Product Portfolio
  18. 8.3.5 Medunik Recent Developments
  19. 8.4 Lee's Pharmaceutical
  20. 8.4.1 Lee's Pharmaceutical Company Information
  21. 8.4.2 Lee's Pharmaceutical Business Overview
  22. 8.4.3 Lee's Pharmaceutical Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lee's Pharmaceutical Urea Cycle Disorder Agent Product Portfolio
  24. 8.4.5 Lee's Pharmaceutical Recent Developments
  25. 8.5 Immedica
  26. 8.5.1 Immedica Company Information
  27. 8.5.2 Immedica Business Overview
  28. 8.5.3 Immedica Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Immedica Urea Cycle Disorder Agent Product Portfolio
  30. 8.5.5 Immedica Recent Developments
  31. 8.6 Horizon Pharma
  32. 8.6.1 Horizon Pharma Company Information
  33. 8.6.2 Horizon Pharma Business Overview
  34. 8.6.3 Horizon Pharma Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Horizon Pharma Urea Cycle Disorder Agent Product Portfolio
  36. 8.6.5 Horizon Pharma Recent Developments
  37. 8.7 Acer Therapeutics
  38. 8.7.1 Acer Therapeutics Company Information
  39. 8.7.2 Acer Therapeutics Business Overview
  40. 8.7.3 Acer Therapeutics Urea Cycle Disorder Agent Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Acer Therapeutics Urea Cycle Disorder Agent Product Portfolio
  42. 8.7.5 Acer Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst